Philadelphia, Pennsylvania 19104


RGX-111 is a gene therapy which is intended to deliver a functional copy of the α-L-iduronidase (IDUA) gene to the central nervous system. This is a safety and dose ranging study to determine whether RGX-111 is safe and tolerated by patients with MPS I.

Study summary:

Mucopolysaccharidosis type I (MPS I) is a rare recessive genetic disease caused by a deficiency of α-L-iduronidase (IDUA) leading to an accumulation of glycosaminoglycans (GAGs) in tissues of patients with MPS I. While currently available therapies, enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), provide clinical benefit over untreated disease progression, they still possess significant limitations. ERT does not cross the blood-brain barrier and, therefore, does not treat the central nervous system (CNS) effects of the disease, and HSCT has clinically relevant morbidity and mortality and is not able to completely treat the CNS effects. RGX-111 is designed to deliver a functioning gene enabling the production of IDUA in the brain. This is a Phase I, first-in-human, multicenter, open-label, dose escalation study of RGX-111. Two, one time doses of RGX-111 will be studied in approximately 5 subjects who have MPS I. Safety will be the primary focus for the initial 24 weeks after treatment (primary study period) whereupon, subjects will continue to be assessed (safety and efficacy) for up to a total of 104 weeks following treatment with RGX-111.


Inclusion Criteria: - Must meet any of the following criteria: - Has documented evidence of early- stage neurocognitive deficit due to MPS I, defined as either of the following: 1. A score of ≥ 1 standard deviation below mean on IQ testing or in 1 domain of neuropsychological function ( verbal comprehension, attention, or perceptual reasoning). 2. A decline of >1 standard deviation on sequential testing - Patient or Patient's legal guardian must be willing and able to provide written, signed informed consent. Exclusion Criteria: - Has contraindications for intracisternal injection or lumbar puncture - Has contraindications for immunosuppressive therapy - Has neurocognitive deficit not attributable to MPS I or diagnosis of a neuropsychiatric condition - Received intrathecal (IT) laronidase at any time and experienced a significant AE considered related to IT administration - Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at screening, unless the subject has a previously known history of Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin <35% of total bilirubin.



Primary Contact:

Jacob Wesley, Pharm D, MS
Phone: 240-552-8181

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19104
United States

Tracey Sikora
Phone: 215-615-3238

Site Status: Recruiting

Data Source:

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.